Generated by AI
Novavax Inc. is a biotechnology company focused on developing and commercializing vaccines that address serious infectious diseases. Novavax Inc. uses a proprietary recombinant protein platform paired with its Matrix-M adjuvant technology to support immune responses across its vaccine portfolio. Its current products and programs include COVID-19 vaccines marketed under the Nuvaxovid brand and the R21/Matrix-M malaria vaccine, along with research efforts aimed at additional infectious disease targets. The company serves global public health markets through vaccine development, manufacturing, and commercialization activities, and it also works with partners and institutions involved in vaccine supply and distribution. Headquartered in Gaithersburg, Maryland, Novavax Inc. remains recognized for its vaccine-focused business model and its role in advancing protein-based immunization technologies.
Website21 Firstfield Road
Gaithersburg, MD, 20878
United States
The latest articles about NVAX.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 13's posts. Generated by AI.
Investors talking about NVAX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.